Cannalean Biotechs Overview
CannaLean Biotechs is committed to the research and development of a proprietary formulation of cannabidiol (CBD) and chitosan that can potentially benefit millions of patients with dyslipidemia. CannaLean uses a synthetic form of CBD, a non-psychotropic component of cannabis, with chitosan, a biocompatible, non-toxic, and non-immunogenic compound that enhances the potential of CBD to reduce lipid blood levels. The company's preliminary results show the effect of the formulation on cholesterol and triglyceride reduction. CannaLean Biotechs was established in partnership with Mor Research Applications.
Latest News
growth-positive
CannaLean Biotechs Announces a Phase 2a Clinical Trial of Cannabidiol-Based Formulation for Lowering Blood Cholesterol Levels
CannaLean Biotechs, an Israel-based clinical stage company, has announced the commencement of its phase 2a clinical trial for a novel formulation of Cannabidiol (CBD) and Chitosan aimed at lowering blood cholesterol levels in patients with hyperlipidemia. The trial will include up to 60 participants and will evaluate the tolerability, safety, and efficacy of the formulation. CannaLean is also planning to start a second phase 2a clinical trial in 2022 to evaluate the safety and efficacy of the new formulation in patients with high levels of triglycerides.
InvestmentExpand
Lower blood lipids: can you eat a cheeseburger and have a strong heart?
growth-positive
CannaLean Develops New Cannabidiol & Chitosan Formulation to Safely Lower Cholesterol and Triglyceride Levels;A Stain Alternative With Fewer Risks
CannaLean, an Israeli company, has completed in vivo studies showing a significant decrease in cholesterol/triglyceride levels with their novel formulation of Cannabidiol (CBD) and Chitosan. The company aims to develop a safe solution for treating dyslipidemia without the side effects of current therapies. CannaLeans formulation has shown positive results in animal models and they are looking forward to upcoming clinical trials. The company has established a partnership with MOR Research Applications, allowing them to reach a large number of patients and data.
Customers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Pre-Funding |
| Rounds | 0 |
| Investors | 0 |
Team Members
6
Employees: 1-10
Web & Social Links
| Website | www.cannaleanbio.com |
Locations
Baruch Hirsch Street 14, Bnei Brak, Israel
Photos & Videos
1 item(s)
Cannalean Biotechs Business
Business models
B2B
Product stage
Clinical Trial
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentMedical CannabisTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsHealthcarePatientsCore Technology
BiologicalsHerbalsTags (8)
cannabismedical-cannabistreatmentsmetabolic-diseasepatientspharma-companiesvascularbiotechnologyCannalean Biotechs Financials
Undisclosed
Total funding
—
Capital raised
Undisclosed
Last funding
Pre-Funding
Funding stage
0
Total rounds
0
Investors
Cannalean Biotechs Lifecycle
Cannalean Biotechs News
3 articles
growth-positive
CannaLean Biotechs Announces a Phase 2a Clinical Trial of Cannabidiol-Based Formulation for Lowering Blood Cholesterol Levels
CannaLean Biotechs, an Israel-based clinical stage company, has announced the commencement of its phase 2a clinical trial for a novel formulation of Cannabidiol (CBD) and Chitosan aimed at lowering blood cholesterol levels in patients with hyperlipidemia. The trial will include up to 60 participants and will evaluate the tolerability, safety, and efficacy of the formulation. CannaLean is also planning to start a second phase 2a clinical trial in 2022 to evaluate the safety and efficacy of the new formulation in patients with high levels of triglycerides.
InvestmentExpand
Lower blood lipids: can you eat a cheeseburger and have a strong heart?
growth-positive
CannaLean Develops New Cannabidiol & Chitosan Formulation to Safely Lower Cholesterol and Triglyceride Levels;A Stain Alternative With Fewer Risks
CannaLean, an Israeli company, has completed in vivo studies showing a significant decrease in cholesterol/triglyceride levels with their novel formulation of Cannabidiol (CBD) and Chitosan. The company aims to develop a safe solution for treating dyslipidemia without the side effects of current therapies. CannaLeans formulation has shown positive results in animal models and they are looking forward to upcoming clinical trials. The company has established a partnership with MOR Research Applications, allowing them to reach a large number of patients and data.
Customers
Cannalean Biotechs Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 3 |
| Team members | 6 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 11 classification IDs that could be used for matching.
Cannalean Biotechs Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 89/100 |
| Missing | funding rounds, markets, not claimed |
| BI Verification | Hilla Gorokhovsky |
| Registrar ID | 515819209 |
| Crunchbase | cannalean-biotechs |
| Phone | +97236176644 |
| Creator | Yotam Maman |
| Creator email | yotamm1988@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2024-05-29T00:00:00.000Z |
| Created | 2019-10-30T00:00:00.000Z |